Cas:544440-95-1 3-chloro-N-[(4-fluorophenyl)methyl]propanamide manufacturer & supplier

Chemical Name:3-chloro-N-[(4-fluorophenyl)methyl]propanamide

CAS.NO:544440-95-1

Synonyms:3-chloro-N-[(4-fluorophenyl)methyl]propanamide

Molecular Formula:C₁₀H₁₁ClFNO

Molecular Weight:215.65200

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:392.2ºC at 760 mmHg

Density:1.219g/cm3

Index of Refraction:1.517

PSA:29.10000

Exact Mass:215.05100

LogP:2.46170

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-chloro-N-[(4-fluorophenyl)methyl]propanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-chloro-N-[(4-fluorophenyl)methyl]propanamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-chloro-N-[(4-fluorophenyl)methyl]propanamide Use and application,3-chloro-N-[(4-fluorophenyl)methyl]propanamide technical grade,usp/ep/jp grade.

Related News: Cost: Hedge prices of thick product lines + self-produced intermediates fluctuate, and sufficient supply of upstream raw materials can significantly promote the production of APIs. 3-chloro-N-[(4-fluorophenyl)methyl]propanamide manufacturer In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. 3-chloro-N-[(4-fluorophenyl)methyl]propanamide supplier GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� 3-chloro-N-[(4-fluorophenyl)methyl]propanamide vendor GlaxoSmithKline��s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection. 3-chloro-N-[(4-fluorophenyl)methyl]propanamide factory In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.